Retina World Congress: Dr. Carl Regillo Ixo-vec

Retina World Congress Recap! Earlier this month, Dr. Carl Regillo, Director of Wills Eye Hospital Retina Service, presented preliminary data from the Phase 2 LUNA Study and three-year results from the Phase 1 OPTIC Extension Trial of Ixo-vec (ixoberogene soroparvovec) intravitreal gene therapy for nAMD. According to Dr. Regillo, the OPTIC long-term extension study demonstrated that a single IVT injection of Ixo-vec provides a durable clinical benefit and substantially reduces treatment burden for at least three years. The study showed an 84%-95% reduction in annualized anti-VEGF injections, with 53%-73% of participants remaining supplemental injection-free in year three. The LUNA Phase 2 study indicated that BCVA was maintained and CST was reduced and remained stable at both Ixo-vec doses through week 26. There was a ≥90% reduction in annualized anti-VEGF injections in both dose groups, and 85%-68% of patients remained free of injections at six months at the 2x1011 and 6x1010 doses, respectively. A prespecified interim analysis will be conducted when all participants complete their 26-week study visit. Financial Disclosures: Dr. Regillo is a consultant for Adverum References: Regillo, C. ADVM-022 Intravitreal Gene Therapy for nAMD: Preliminary Data from the Phase 2 LUNA Study and 3-Year Results from the Phase 1 OPTIC Extension Trial. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.